Pioglitazone for advanced fibrosis in nonalcoholic steatohepatitis: New evidence, new challenges

Hepatology

Volumn 65, Issue 3, 2017, Pages 1058-1061

  Musso, Giovanni ^a   Cassader, Maurizio ^b   Paschetta, Elena ^a   Gambino, Roberto ^b  

^a GRADENIGO HOSPITAL   (Italy)

^b UNIVERSITY OF TURIN   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

PIOGLITAZONE; 2,4 THIAZOLIDINEDIONE DERIVATIVE; ANTIDIABETIC AGENT;

ARTICLE; BLADDER CANCER; CLINICAL EVALUATION; CLINICAL PRACTICE; DRUG SAFETY; EDEMA; FLUID RETENTION; HUMAN; LIVER FIBROSIS; LIVER HISTOLOGY; LIVER TRANSPLANTATION; NONALCOHOLIC FATTY LIVER; OPEN STUDY; OSTEOLYSIS; PRIORITY JOURNAL; TREATMENT DURATION; WEIGHT GAIN; FIBROSIS;

FIBROSIS; HUMANS; HYPOGLYCEMIC AGENTS; NON-ALCOHOLIC FATTY LIVER DISEASE; THIAZOLIDINEDIONES;

EID: 85011344917     PISSN: 02709139     EISSN: 15273350     Source Type: Journal    
DOI: 10.1002/hep.28960     Document Type: Article

References (8)

1. Cusi K, Orsak B, Bril F, Lomonaco R, Hecht J, Ortiz-Lopez C, et al. Long-term pioglitazone treatment for patients with NASH and prediabetes or type 2 diabetes mellitus: a randomized, controlled trial. Ann Intern Med 2016 Jun 21. doi: 10.7326/M15-1774. [Epub ahead of print]
2. National Institute of Care and Health Excellence (NICE) guidelines. Non-alcoholic fatty liver disease (NAFLD): 1 assessment and management. www.nice.org.uk/guidance/indevelopment/gid-cgwave0692. Accessed on August 30, 2016.
3. Musso G, Cassader M, Gambino R. Non-alcoholic steatohepatitis: emerging molecular targets and therapeutic strategies. Nat Rev Drug Discov 2016;15:249-274.
4. Musso G, Cassader M, Paschetta E, Gambino R. The effect of thiazolidinediones on advanced liver fibrosis in nonalcoholic steatohepatitis: a meta-analysis of randomized trials. JAMA Int Med 2016. doi: 10.1001/jamainternmed.2016.9607. In press.
5. Ekstedt M, Hagström H, Nasr P, Fredrikson M. Fibrosis stage is the strongest predictor for disease-specific mortality in NAFLD after up to 33 years of follow-up. Hepatology 2015;61:1547-1554.
6. Levin D, Bell S, Sund R, Hartikainen SA, Tuomilehto J, Pukkala E, et al. Pioglitazone and bladder cancer risk: a multipopulation pooled, cumulative exposure analysis. Diabetologia 2015;58:493-504.
7. Karsdal MA, Henriksen K, Genovese F, Leeming DJ. Serum endotrophin identifies optimal responders to PPARγ agonists in type 2 diabetes. Diabetologia 2016 Sep 8. doi: 10.1007/s00125-016-4094-1. [Epub ahead of print]
8. McCommis KS, McDonald WG, Colca JR. Modulating mitochondrial pyruvate carrier activity decreases hepatic fibrosis in a mouse model of NASH. Diabetes 2016; 65(S1):A36.